Literature DB >> 25281420

Modeling cancer-immune responses to therapy.

L G dePillis1, A Eladdadi, A E Radunskaya.   

Abstract

Cancer therapies that harness the actions of the immune response, such as targeted monoclonal antibody treatments and therapeutic vaccines, are relatively new and promising in the landscape of cancer treatment options. Mathematical modeling and simulation of immune-modifying therapies can help to offset the costs of drug discovery and development, and encourage progress toward new immunotherapies. Despite advances in cancer immunology research, questions such as how the immune system interacts with a growing tumor, and which components of the immune system play significant roles in responding to immunotherapy are still not well understood. Mathematical modeling and simulation are powerful tools that provide an analytical framework in which to address such questions. A quantitative understanding of the kinetics of the immune response to treatment is crucial in designing treatment strategies, such as dosing, timing, and predicting the response to a specific treatment. These models can be used both descriptively and predictively. In this chapter, various mathematical models that address different cancer treatments, including cytotoxic chemotherapy, immunotherapy, and combinations of both treatments, are presented. The aim of this chapter is to highlight the importance of mathematical modeling and simulation in the design of immunotherapy protocols for cancer treatment. The results demonstrate the power of these approaches in explaining determinants that are fundamental to cancer-immune dynamics, therapeutic success, and the development of efficient therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25281420     DOI: 10.1007/s10928-014-9386-9

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  59 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

3.  A mathematical model of receptor-mediated apoptosis: dying to know why fasl is a trimer.

Authors:  Ronald Lai; Trachette L Jackson
Journal:  Math Biosci Eng       Date:  2004-09       Impact factor: 2.080

4.  Measurement and management of carcinoma of the breast.

Authors:  R H Thomlinson
Journal:  Clin Radiol       Date:  1982-09       Impact factor: 2.350

5.  A cellular automata model of tumor-immune system interactions.

Authors:  D G Mallet; L G De Pillis
Journal:  J Theor Biol       Date:  2005-09-15       Impact factor: 2.691

6.  Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; C A Seipp; J H Einhorn; D E White; S M Steinberg
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

7.  Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model.

Authors:  Paul K Newton; Jeremy Mason; Kelly Bethel; Lyudmila Bazhenova; Jorge Nieva; Larry Norton; Peter Kuhn
Journal:  Cancer Res       Date:  2013-02-27       Impact factor: 12.701

8.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

9.  The emerging low-dose therapy for advanced cancers.

Authors:  Jahangir Satti
Journal:  Dose Response       Date:  2009-03-24       Impact factor: 2.658

10.  Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

Authors:  N J Meropol; G M Barresi; T A Fehniger; J Hitt; M Franklin; M A Caligiuri
Journal:  Cancer Immunol Immunother       Date:  1998-08       Impact factor: 6.968

View more
  15 in total

1.  Optimization of combination therapy for chronic myeloid leukemia with dosing constraints.

Authors:  Helen Moore; Lewis Strauss; Urszula Ledzewicz
Journal:  J Math Biol       Date:  2018-07-10       Impact factor: 2.259

Review 2.  Mathematical modeling of tumor-immune cell interactions.

Authors:  Grace E Mahlbacher; Kara C Reihmer; Hermann B Frieboes
Journal:  J Theor Biol       Date:  2019-03-02       Impact factor: 2.691

Review 3.  Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond.

Authors:  Cristina Migali; Monica Milano; Dario Trapani; Carmen Criscitiello; Angela Esposito; Marzia Locatelli; Ida Minchella; Giuseppe Curigliano
Journal:  Ther Adv Med Oncol       Date:  2016-07-10       Impact factor: 8.168

4.  Asymptotic dynamics of some t-periodic one-dimensional model with application to prostate cancer immunotherapy.

Authors:  U Foryś; M Bodnar; Y Kogan
Journal:  J Math Biol       Date:  2016-02-20       Impact factor: 2.259

5.  A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition.

Authors:  Chang Gong; Oleg Milberg; Bing Wang; Paolo Vicini; Rajesh Narwal; Lorin Roskos; Aleksander S Popel
Journal:  J R Soc Interface       Date:  2017-09       Impact factor: 4.118

Review 6.  Fighting Cancer with Mathematics and Viruses.

Authors:  Daniel N Santiago; Johannes P W Heidbuechel; Wendy M Kandell; Rachel Walker; Julie Djeu; Christine E Engeland; Daniel Abate-Daga; Heiko Enderling
Journal:  Viruses       Date:  2017-08-23       Impact factor: 5.048

Review 7.  Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.

Authors:  Kirill Peskov; Ivan Azarov; Lulu Chu; Veronika Voronova; Yuri Kosinsky; Gabriel Helmlinger
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

8.  An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer.

Authors:  Qing Wang; Zhijun Wang; Yan Wu; David J Klinke
Journal:  BMC Cancer       Date:  2020-01-08       Impact factor: 4.430

9.  Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept.

Authors:  Odelaisy León-Triana; Antonio Pérez-Martínez; Manuel Ramírez-Orellana; Víctor M Pérez-García
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

10.  A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade.

Authors:  Oleg Milberg; Chang Gong; Mohammad Jafarnejad; Imke H Bartelink; Bing Wang; Paolo Vicini; Rajesh Narwal; Lorin Roskos; Aleksander S Popel
Journal:  Sci Rep       Date:  2019-08-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.